Recent Advances in Diagnosis and Treatment Strategies for Multiple Primary Lung Cancer.
10.3779/j.issn.1009-3419.2023.102.44
- Author:
Bangsheng LI
1
;
Zhenghong YANG
1
;
Yingding ZHAO
1
;
Ying CHEN
1
;
Yunchao HUANG
1
Author Information
1. Department of Thoracic Surgery I, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China.
- Publication Type:Journal Article
- Keywords:
Ablation;
Immunotherapy;
Lung neoplasms;
Next-generation sequencing;
Radiation therapy;
Surgery;
Targeted therapy
- MeSH:
Humans;
Lung Neoplasms/therapy*;
Early Detection of Cancer;
Lung/surgery*;
Treatment Outcome;
Radiosurgery/methods*;
Neoplasms, Multiple Primary/pathology*
- From:
Chinese Journal of Lung Cancer
2023;26(11):863-873
- CountryChina
- Language:Chinese
-
Abstract:
As the utilization of computed tomography in lung cancer screening becomes more prevalent in the post-pandemic era, the incidence of multiple primary lung cancer (MPLC) has surged in various countries and regions. Despite the continued application of advanced histologic and sequencing technologies in this research field, the differentiation between MPLC and intrapulmonary metastasis (IM) remains challenging. In recent years, the specific mechanisms of genetic and environmental factors in MPLC have gradually come to light. Lobectomy still predominates in the treatment of MPLC, but the observation that tumor-specific sublobar resection has not detrimentally impacted survival appears to be a viable option. With the evolution of paradigms, the amalgamated treatment, primarily surgical, is an emerging trend. Among these, stereotactic ablative radiotherapy (SABR) and lung ablation techniques have emerged as efficacious treatments for early unresectable tumors and control of residual lesions. Furthermore, targeted therapies for driver-positive mutations and immunotherapy have demonstrated promising outcomes in the postoperative adjuvant phase. In this manuscript, we intend to provide an overview of the management of MPLC based on the latest discoveries.
.
